New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
12:39 EDTCGENCompugen jumps after announcing newly discovered proteins
Compugen (CGEN) is rallying after the company announced earlier today that it has extended discovery capabilities to additional immunomodulatory proteins. WHAT'S NOTABLE: Compugen announced the extension of its predictive discovery capability to identify immunomodulatory proteins in addition to the B7/CD28-like proteins that have been the focus of the companyís pipeline program to date. The initial utilization of this extended capability resulted in the discovery of four novel immunomodulatory proteins predicted to act as immune checkpoints. The newly discovered proteins have been added to the companyís pipeline program as potential targets for cancer immunotherapy. Dr. Cohen-Dayag, CEO of Compugen, noted "We are of course very proud that in less than four years, we have established a growing position in this field, including a substantial early-stage pipeline of therapeutic product candidates for both oncology and immunology, based largely on our B7/CD28-like protein candidate discoveries. With todayís announcement, we are further broadening our early-stage pipeline with additional immunomodulatory opportunities and again demonstrating the power and flexibility of our predictive discovery capabilities." PRICE ACTION: In afternoon trading, Compugen 's stock rallied 51c, or almost 6%, to $9.39.
News For CGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
07:07 EDTCGENCompugen enters into research collaboration with Johns Hopkins University
Compugen announced the initiation of a multi-year research collaboration with Johns Hopkins University, School of Medicine, under the direction of Prof. Drew Pardoll and Dr. Charles Drake. Prof. Pardoll and Dr. Drake, members of Compugenís Scientific Advisory Board, are pioneers in the field of immuno-oncology. The collaboration will focus on further evaluation of selected novel B7/CD28-like immune checkpoint candidates discovered by Compugen for the potential treatment of cancer. This evaluation will include the candidatesí differentiation profile with respect to known checkpoints and their potential to serve either for monotherapy or in combination with other cancer treatments. This collaborative research will expand Compugenís ongoing assessment of the biology and mechanism of actions of its novel B7/CD28-like immune checkpoint proteins, and provide access to the world-class immuno-oncology research tools and expertise at Johns Hopkins University. The specific studies under the collaboration will assist Compugen in further substantiating the potential of its novel proteins as targets for cancer immunotherapy. It is anticipated that the results of this collaboration will significantly broaden the underlying scientific knowledge of Compugenís targets and will support their translation toward the clinic.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use